Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study.

Identifieur interne : 000B91 ( Ncbi/Curation ); précédent : 000B90; suivant : 000B92

Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study.

Auteurs : Jau-Shin Lou [États-Unis] ; Greg Kearns ; Theodore Benice ; Barry Oken ; Gary Sexton ; John Nutt

Source :

RBID : pubmed:14534913

English descriptors

Abstract

We quantitatively investigated the effect of carbidopa/levodopa (25/100) on physical fatigue during finger tapping and force generation in a double-blind, placebo-controlled crossover study. Parkinson's disease (PD) subjects were randomly assigned to carbidopa/levodopa or placebo for Visit 1 or 2 and participated in the following two studies: (1) Finger tapping. Twenty-five PD patients used their index fingers to strike two keys 20 cm apart on a musical instrument digital interface (MIDI) keyboard. The slopes of the regression line of dwell time and movement time were used to assess the rate of fatigue development. (2) Force generation. Twelve PD patients contracted the wrist extensors maximally to obtain a baseline maximum voluntary contraction (BMVC) force. Then they repetitively contracted the wrist extensors at 50% of the BMVC for 7 seconds and rested for 3 seconds. An interval maximum voluntary contraction (IMVC) was measured every three repetitions. Fatigue was defined as an IMVC of less than 60% of the BMVC. The slope of the regression line of IMVC was used to assess the rate of force decline. These two studies were repeated 1 hour after carbidopa/levodopa (25/100) or placebo. Subjects filled out the Multidimensional Fatigue Inventory (MFI) at the beginning of the first visit. Results showed that the slope of dwell time decreased with levodopa but not with placebo (P = 0.004). The rate of force decline also decreased with levodopa but not with placebo (P = 0.01). The subscores in the dimension of physical fatigue in the MFI did not correlate with the rate changes in dwell time or the rate changes in force decline. We concluded that (1) levodopa improves physical fatigue in finger tapping and force generation, (2) physical fatigue in Parkinson's disease is at least partially related to dopamine deficiency, and (3) the MFI measures different aspects of physical fatigue compared with those measured by finger tapping and force generation.

DOI: 10.1002/mds.10505
PubMed: 14534913

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:14534913

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study.</title>
<author>
<name sortKey="Lou, Jau Shin" sort="Lou, Jau Shin" uniqKey="Lou J" first="Jau-Shin" last="Lou">Jau-Shin Lou</name>
<affiliation wicri:level="4">
<nlm:affiliation>Department of Neurology, Oregon Health & Science University, Portland, Oregon 97239, USA. louja@ohsu.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Oregon Health & Science University, Portland, Oregon 97239</wicri:regionArea>
<orgName type="university">Université des sciences et de la médecine de l'Oregon</orgName>
<placeName>
<settlement type="city">Portland</settlement>
<region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kearns, Greg" sort="Kearns, Greg" uniqKey="Kearns G" first="Greg" last="Kearns">Greg Kearns</name>
</author>
<author>
<name sortKey="Benice, Theodore" sort="Benice, Theodore" uniqKey="Benice T" first="Theodore" last="Benice">Theodore Benice</name>
</author>
<author>
<name sortKey="Oken, Barry" sort="Oken, Barry" uniqKey="Oken B" first="Barry" last="Oken">Barry Oken</name>
</author>
<author>
<name sortKey="Sexton, Gary" sort="Sexton, Gary" uniqKey="Sexton G" first="Gary" last="Sexton">Gary Sexton</name>
</author>
<author>
<name sortKey="Nutt, John" sort="Nutt, John" uniqKey="Nutt J" first="John" last="Nutt">John Nutt</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2003">2003</date>
<idno type="RBID">pubmed:14534913</idno>
<idno type="pmid">14534913</idno>
<idno type="doi">10.1002/mds.10505</idno>
<idno type="wicri:Area/PubMed/Corpus">003673</idno>
<idno type="wicri:Area/PubMed/Curation">003673</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003745</idno>
<idno type="wicri:Area/Ncbi/Merge">000B91</idno>
<idno type="wicri:Area/Ncbi/Curation">000B91</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study.</title>
<author>
<name sortKey="Lou, Jau Shin" sort="Lou, Jau Shin" uniqKey="Lou J" first="Jau-Shin" last="Lou">Jau-Shin Lou</name>
<affiliation wicri:level="4">
<nlm:affiliation>Department of Neurology, Oregon Health & Science University, Portland, Oregon 97239, USA. louja@ohsu.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Oregon Health & Science University, Portland, Oregon 97239</wicri:regionArea>
<orgName type="university">Université des sciences et de la médecine de l'Oregon</orgName>
<placeName>
<settlement type="city">Portland</settlement>
<region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kearns, Greg" sort="Kearns, Greg" uniqKey="Kearns G" first="Greg" last="Kearns">Greg Kearns</name>
</author>
<author>
<name sortKey="Benice, Theodore" sort="Benice, Theodore" uniqKey="Benice T" first="Theodore" last="Benice">Theodore Benice</name>
</author>
<author>
<name sortKey="Oken, Barry" sort="Oken, Barry" uniqKey="Oken B" first="Barry" last="Oken">Barry Oken</name>
</author>
<author>
<name sortKey="Sexton, Gary" sort="Sexton, Gary" uniqKey="Sexton G" first="Gary" last="Sexton">Gary Sexton</name>
</author>
<author>
<name sortKey="Nutt, John" sort="Nutt, John" uniqKey="Nutt J" first="John" last="Nutt">John Nutt</name>
</author>
</analytic>
<series>
<title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="2003" type="published">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Aged</term>
<term>Cross-Over Studies</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Drug Combinations</term>
<term>Fatigue (drug therapy)</term>
<term>Fatigue (etiology)</term>
<term>Female</term>
<term>Fingers (physiology)</term>
<term>Humans</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Motor Activity (drug effects)</term>
<term>Movement (drug effects)</term>
<term>Muscle Contraction (drug effects)</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Psychomotor Performance (drug effects)</term>
<term>Questionnaires</term>
<term>Regression Analysis</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Dopamine Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Motor Activity</term>
<term>Movement</term>
<term>Muscle Contraction</term>
<term>Psychomotor Performance</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Fatigue</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en">
<term>Fatigue</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Fingers</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Aged</term>
<term>Cross-Over Studies</term>
<term>Double-Blind Method</term>
<term>Drug Combinations</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Questionnaires</term>
<term>Regression Analysis</term>
<term>Time Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">We quantitatively investigated the effect of carbidopa/levodopa (25/100) on physical fatigue during finger tapping and force generation in a double-blind, placebo-controlled crossover study. Parkinson's disease (PD) subjects were randomly assigned to carbidopa/levodopa or placebo for Visit 1 or 2 and participated in the following two studies: (1) Finger tapping. Twenty-five PD patients used their index fingers to strike two keys 20 cm apart on a musical instrument digital interface (MIDI) keyboard. The slopes of the regression line of dwell time and movement time were used to assess the rate of fatigue development. (2) Force generation. Twelve PD patients contracted the wrist extensors maximally to obtain a baseline maximum voluntary contraction (BMVC) force. Then they repetitively contracted the wrist extensors at 50% of the BMVC for 7 seconds and rested for 3 seconds. An interval maximum voluntary contraction (IMVC) was measured every three repetitions. Fatigue was defined as an IMVC of less than 60% of the BMVC. The slope of the regression line of IMVC was used to assess the rate of force decline. These two studies were repeated 1 hour after carbidopa/levodopa (25/100) or placebo. Subjects filled out the Multidimensional Fatigue Inventory (MFI) at the beginning of the first visit. Results showed that the slope of dwell time decreased with levodopa but not with placebo (P = 0.004). The rate of force decline also decreased with levodopa but not with placebo (P = 0.01). The subscores in the dimension of physical fatigue in the MFI did not correlate with the rate changes in dwell time or the rate changes in force decline. We concluded that (1) levodopa improves physical fatigue in finger tapping and force generation, (2) physical fatigue in Parkinson's disease is at least partially related to dopamine deficiency, and (3) the MFI measures different aspects of physical fatigue compared with those measured by finger tapping and force generation.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B91 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000B91 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:14534913
   |texte=   Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i   -Sk "pubmed:14534913" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3 

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024